Logo

Amgen Report Results for ABP 959 in Clinical Trial for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Share this
Amgen

Amgen Report Results for ABP 959 in Clinical Trial for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Shots: 

  • The company presented the results from the parallel & crossover comparisons along with the PK analysis of ABP 959 vs Soliris in patients with PNH. The results were presented by the company at the ASH 2023  
  • The results from both the parallel & crossover comparisons depicted similar efficacy data as determined by hemolysis in patients along with a similar PK between the 2 treatments seen through the analyses of serum total & unbound PK concentrations  
  • ABP 959 has already been approved in the EU with brand name Bekemv whereas its originator Soliris is approved in many indications incl. PNH, aHUS, gMG & NSOD. Post settlement with Alexion biosimilar can’t be launched in US till Mar 1, 2025 

Ref: Amgen | Image: Amgen

Related News:- Q32 Bio Signs an Agreement with Amgen to Retrieve the Rights to Bempikibart (ADX-914) for Autoimmune Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions